Sds Optic SA
WSE:SDS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (32.4), the stock would be worth zł-40.15 (769% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.8 | zł6 |
0%
|
| Industry Average | 32.4 | zł-40.15 |
-769%
|
| Country Average | 18.5 | zł-22.88 |
-481%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
S
|
Sds Optic SA
WSE:SDS
|
37.8m PLN | -4.8 | -11.9 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 65.3 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 29 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 20.7 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 27.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 29.3 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 37 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 46 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 17.2 | 20.1 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 7.5 |
| Median | 18.5 |
| 70th Percentile | 27.4 |
| Max | 2 825.7 |
Other Multiples
Sds Optic SA
Glance View
SDS Optic SA engages in the development of biochemistry, engineering, and fiber optic technologies solutions, which can be used in cancer diagnosis and treatment. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2022-03-15. The Company’s primary research activity relates to the oncology sector. The Firm wishes to develop a method for early breast cancer diagnosis. The current method of diagnosis relies on biopsy and histopathology. The purpose of the tests is to identify cancer markers. The firm tries to implement InProbe method, which is faster and more accurate- the method should be able to provide results within 20 minutes. The firm is also engaged in research regarding different kinds of diseases such as fungal diseases. The firm cooperates with specialists from different fields such as biology, medicine, technology, and sciences related to medicine.
